<DOC>
	<DOCNO>NCT00039117</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine oblimersen cytarabine daunorubicin treat old patient previously untreated acute myeloid leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Oblimersen may help cytarabine daunorubicin kill cancer cell make sensitive chemotherapy .</brief_summary>
	<brief_title>Oblimersen , Cytarabine , Daunorubicin Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose daunorubicin combination cytarabine oblimersen old patient previously untreated acute myeloid leukemia . II . Determine qualitative quantitative toxic effect regimen patient . III . Determine pharmacokinetics oblimersen regimen patient . IV . Determine disease-free survival overall survival patient treat regimen . V. Assess spontaneous rate apoptosis leukemic blast patient initiation treatment oblimersen . VI . Determine therapeutic response ( complete remission ) patient treat regimen . OUTLINE : This dose-escalation study daunorubicin . Patients stratify accord disease status ( primary v secondary ) . INDUCTION THERAPY : Patients receive oblimersen ( G3139 ) IV continuously day 1-10 cytarabine IV continuously day 4-10 . Patients also receive daunorubicin IV daily day 4-6 . Patients bone marrow cellularity least 20 % least 5 % leukemic blast day 17 evidence refractory disease receive second induction comprise G3139 IV continuously day 1-8 , cytarabine IV continuously day 4-8 , daunorubicin IV day 4-5 . CONSOLIDATION THERAPY : Beginning sooner 14 day hematologic recovery induction therapy , patient receive G3139 IV continuously day 1-8 cytarabine IV 4 hour day 4-8 . Patients receive second course consolidation therapy sooner 14 day hematologic recovery first course . Cohorts 3-6 patient receive escalate dos daunorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Histologically confirm primary secondary acute myeloid leukemia ( AML ) More 20 % bone marrow blast Myelodysplastic syndrome ( MDS ) chronic myeloproliferative disorder antecedent AML allow Therapyrelated AML allow No acute promyelocytic leukemia At least 4 week Bilirubin great 2 mg/dL ALT AST great 2 time upper limit normal ( unless directly attributable AML ) Creatinine great 2.5 mg/dL Ejection fraction least 50 % MUGA echocardiogram No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No allergy study medication No uncontrolled concurrent illness No serious medical psychiatric illness would preclude give informed consent Not pregnant nursing Fertile patient must use effective contraception No prior therapy primary AML except emergency leukapheresis No prior anthracyclines No prior chemotherapy primary AML except hydroxyurea hyperleukocytosis At least 3 month since prior chemotherapy MDS chronic myeloproliferative disorder antecedent AML No concurrent chemotherapy No concurrent corticosteroid antiemetics No concurrent steroid except adrenal failure septic shock No concurrent hormonal therapy except hormone nondiseaserelated condition ( e.g. , insulin diabetes , tamoxifen equivalent breast cancer prevention adjuvant treatment , estrogens progestin gynecologic indication ) No prior radiotherapy primary AML except cranial radiotherapy CNS leukostasis No concurrent palliative radiotherapy No concurrent whole brain radiotherapy No concurrent investigational commercial agent therapies No concurrent cyclooxygenase2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>